Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Trifluoromethanesulfonic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | SNCA | P37840 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CA5A | P35218 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL2123096 | 1.00 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNATDP1KDM4E | |
| Trifluoromethanesulfonic Acid SCHEMBL3621949 | 0.96 | SNCA (0.47) | ALDH1A1SMN1; SMN2LMNATDP1KDM4E | |
| P-Xylene SCHEMBL2990077 | 0.89 | CA2 (0.50) | ALDH1A1SMN1; SMN2LMNATDP1GAA | |
| SCHEMBL3020405 | 0.88 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2LMNATDP1KDM4E | |
| SCHEMBL28268960 | 0.88 | SNCA (0.50) | ALDH1A1SMN1; SMN2LMNATDP1KDM4E | |
| Fluoromethane SCHEMBL20577007 | 0.87 | GAA (0.56) | ALDH1A1SMN1; SMN2LMNATDP1KDM4E | |
| SCHEMBL1705904 | 0.87 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNATDP1KDM4E | |
| P-Xylene SCHEMBL8660591 | 0.87 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNATDP1KDM4E | |
| SCHEMBL31313 | 0.87 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNATDP1KDM4E | |
| SCHEMBL34 | 0.87 | GAA (0.62) | ALDH1A1SMN1; SMN2LMNATDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113735813-A | Photocatalytic synthesis method of 3-trifluoromethylselenocyclochromone compound | 湖南科技学院 | 2021-12-03 | — | — | CN | claimed |
| CN-113024464-A | Method for preparing [60] fullerene tetrahydroquinoline derivative based on triflic acid/p-toluenesulfonic acid catalysis | 湖北大学 | 2021-06-25 | — | — | CN | claimed |
| EP-3442959-A1 | PIPERIDINYLALKYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-02-20 | — | — | EP | claimed |
| WO-2017178515-A1 | PIPERIDINYLALKYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-10-19 | — | — | WO | claimed |
| EP-1716119-B1 | Analogs of benzoquinone-containing ansamycins for the treatment of cancer | INFINITY DISCOVERY INC (US) | 2013-03-06 | — | — | EP | claimed |
| US-20120070374-A1 | Compounds for Non-Invasive Measurement of Aggregates of Amyloid Peptides | TECHNISCHE UNIVERSITAT MUNCHEN (DE) | 2012-03-22 | — | — | US | claimed |
| WO-2010092111-A2 | COMPOUNDS FOR NON-INVASIVE MEASUREMENT OF AGGREGATES OF AMYLOID PEPTIDES | Technische Universität München (DE) | 2010-08-19 | — | — | WO | claimed |
| EP-2218464-A1 | Compounds for non-invasive measurement of aggregates of amyloid peptides | Technische Universität München (DE) | 2010-08-18 | — | — | EP | claimed |
| EP-1861397-A2 | PRODUCTION OF DOLASETRON | TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság (HU) | 2007-12-05 | — | — | EP | claimed |
| WO-2007081889-A9 | PRODUCTION OF DOLASETRON | TEVA GYOGYSZERGYAR ZARTKORUEN (HU) | 2007-09-20 | — | — | WO | claimed |
| WO-2007081890-A2 | PRODUCTION OF DOLASETRON | TEVA GYÓGYSZERGYÁR ZÁRTKÖRÜEN MÜKÖDÖ RÉSZVÉNYTÁRSASÁG (HU) | 2007-07-19 | — | — | WO | claimed |
| US-5905163-A | REDUCTION OF CYANO GROUP BY CATALYTIC HYDROGENATION | MONSANTO COMPANY (US) | 1999-05-18 | — | — | US | claimed |
| EP-0352612-B1 | PROCESS FOR THE PRODUCTION OF A PRINTING PLATE | M.A.N.-ROLAND Druckmaschinen Aktiengesellschaft (DE) | 1993-03-10 | — | — | EP | claimed |
| US-11932695-B2 | Modified antibodies and related compounds, compositions and methods of use | SENSEI BIOTHERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-11873339-B2 | Anti-C10orf54 antibodies and uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2024-01-16 | — | — | US | disclosed |
| EP-4298145-A1 | ONE COMPONENT POLYMERIZABLE COMPOSITION FOR TRICKLE IMPREGNATION | Huntsman Advanced Materials Licensing (Switzerland) GmbH (CH) | 2024-01-03 | — | — | EP | disclosed |
| WO-2005070889-A1 | HERBICIDAL AMIDES | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2001089460-A2 | COLORANT FOR FIBRES CONTAINING KERATIN | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2001-11-29 | — | — | WO | disclosed |
| CN-1290275-A | Catalyst and process for polymerization of cycloolefin | GOODRICH CO B F (US) | 2001-04-04 | — | — | CN | disclosed |
| US-5905163-A | REDUCTION OF CYANO GROUP BY CATALYTIC HYDROGENATION | MONSANTO COMPANY (US) | 1999-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070374-A1 | Compounds for Non-Invasive Measurement of Aggregates of Amyloid Peptides | IAPP, APP, HTT | ALDH1A1 4488/4885SMN1; SMN2 307/4885LMNA 1196/4885 |
| US-11873339-B2 | Anti-C10orf54 antibodies and uses thereof | CD2BP2, DCLRE1B, CLTB | ALDH1A1 3743/4885SMN1; SMN2 1764/4885LMNA 2952/4885 |
| US-11932695-B2 | Modified antibodies and related compounds, compositions and methods of use | FCGR1A, FCGR3B, FCGRT | ALDH1A1 1540/4885SMN1; SMN2 1141/4885LMNA 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.